drugset / Trial / NCT05485558

the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy

NCT05485558

Phase 2 Completed 90 enrolled Tanta University
RandomizedParallel-groupDouble-blindTreatment

Summary

This study aims at investigating the possible efficacy and safety of N-acetyl cysteine as adjuvant therapy in the treatment of drug-resistant epilepsy

Timeline

Start
2022-09-15
Primary completion
2024-06-01
Completion
2025-01-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator N-acetylcysteine Small molecule 10 mg/kg
Comparator N-acetylcysteine Small molecule 40 mg/kg

Indications